Bristol-Myers Squibb reports positive clinical trial results as a combination therapy featuring nivolumab reduces disease progression risk by 27% with a median survival of 11.7 months.
Nivolumab is part of the combination therapy that showed improved progression-free survival, potentially benefiting BMS's oncology franchise.
Bristol-Myers Squibb's nivolumab, when paired with oral HBI-8000, achieved a statistically significant improvement in progression-free survival. The combination therapy reduced the risk of disease progression or death by 27% compared to nivolumab monotherapy, with a median progression-free survival reaching 11.7 months.
The study demonstrated a statistically significant improvement in progression-free survival, reducing the risk of disease progression or death by 27% compared to nivolumab alone.